Immune marker profiling and PD-L1 expression across Non-Small Cell Lung Cancer mutations

PURPOSE: PD-1/PD-L1 axis inhibitors have been proven effective, especially in patients with tumors expressing Programmed Death Ligand 1 (PD-L1). Their clinical efficacy in patients with epidermal growth factor receptor (EGFR) activating mutations is still unclear, while KRAS mutations seem to be ass...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Toki, Maria I., Mani, Nikita, Smithy, James W., Liu, Yuting, Altan, Mehmet, Wasserman, Brad, Tuktamyshov, Rasikh, Schalper, Kurt, Syrigos, Konstantinos N., Rimm, David L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6251746/
https://ncbi.nlm.nih.gov/pubmed/30267840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.09.012
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados